Published in Ann Surg on July 01, 1988
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. Ann Surg (2000) 1.20
Surgery for distant melanoma metastasis. Cancer J (2012) 1.03
Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol (2005) 0.99
Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg (1998) 0.99
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol (2007) 0.95
Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. Int J Clin Oncol (2010) 0.82
Surgical management of breast cancer liver metastases. HPB (Oxford) (2011) 0.78
Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci (2003) 0.76
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. World J Gastroenterol (2008) 0.76
Resection of hepatic metastases from colorectal cancer. Arch Surg (1984) 4.06
Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg (1984) 3.96
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery (1986) 3.22
Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg (1976) 2.96
Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg (1981) 2.69
Survival after liver resection for secondary tumors. Am J Surg (1978) 2.57
Major hepatic resection. A 25-year experience. Ann Surg (1983) 2.55
Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet (1986) 2.21
Major hepatic resection for metachronous metastases from colon cancer. Ann Surg (1985) 1.89
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg (1985) 1.65
Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg (1978) 1.49
Hepatic resection of metastatic colorectal carcinoma: a ten-year experience. Arch Surg (1982) 1.43
Survival after liver resection for cancer. Cancer (1970) 1.40
Intrahepatic arterial infusion with 5-fluorouracil. Cancer (1971) 1.27
Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet (1969) 1.25
Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon. Am J Surg (1974) 1.22
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer (1984) 1.10
Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer (1986) 1.04
Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer (1986) 1.03
Experience with infusion and resection in cancer of the liver. Surg Gynecol Obstet (1974) 0.98
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
The systemic chemotherapy of hepatic metastases. Semin Oncol (1983) 0.93
Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg (1983) 0.89
Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol (1986) 0.85
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver. Cancer (1967) 0.83
Experiences with regional chemotherapy. Perfusions and intra-arterial infusion. Arch Surg (1962) 0.82
Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. Cancer (1987) 0.81
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. Cancer (1986) 0.78
The use of the implantable chemoinfusion pump in the treatment of hepatic metastases of colorectal cancer. Arch Surg (1986) 0.78
Perfusion for melanoma of the extremities: 6 and one half-years' experience with 221 cases. Proc Natl Cancer Conf (1964) 0.77
Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med (1983) 25.72
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 17.42
Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J Clin Microbiol (1983) 10.23
Escherichia fergusonii and Enterobacter taylorae, two new species of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol (1985) 4.52
H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol (1985) 3.91
Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Ann Intern Med (1984) 3.88
Atypical biogroups of Escherichia coli found in clinical specimens and description of Escherichia hermannii sp. nov. J Clin Microbiol (1982) 3.84
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Characterization of biochemically atypical Vibrio cholerae strains and designation of a new pathogenic species, Vibrio mimicus. J Clin Microbiol (1981) 3.19
High-molecular-weight plasmid correlates with Escherichia coli enteroinvasiveness. Infect Immun (1982) 2.95
Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med (1991) 2.49
Extrachromosomal nature of hydrogen sulfide production in Escherichia coli. J Bacteriol (1971) 2.45
Differential effect of steady versus oscillating flow on bone cells. J Biomech (1998) 2.38
Correlation between adherence to HeLa cells and serogroups, serotypes, and bioserotypes of Escherichia coli. Infect Immun (1985) 2.28
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Enterotoxin-producing Escherichia coli and diarrheal disease in adult travelers: a prospective study. J Infect Dis (1974) 2.19
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA (1997) 2.11
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension (1991) 2.04
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Biochemical and serological characterization of hydrogen sulfide-positive variants of Escherichia coli. Appl Microbiol (1974) 1.89
Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology (1996) 1.87
Response of rat lung to 3,4-benzpyrene administered by intratracheal instillation in infusine with or without carbon black. Br J Cancer (1975) 1.86
Isolated systolic hypertension : prognostic information provided by pulse pressure. Hypertension (1999) 1.83
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Characterization of a preleukemic state induced by Moloney murine leukemia virus: evidence for two infection events during leukemogenesis. Proc Natl Acad Sci U S A (1987) 1.72
Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly). Arch Intern Med (1996) 1.72
A multistate outbreak of infections caused by Yersinia enterocolitica transmitted by pasteurized milk. JAMA (1984) 1.70
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 1.63
The purification and characterization of an extremely thermostable alpha-amylase from the hyperthermophilic archaebacterium Pyrococcus furiosus. J Biol Chem (1993) 1.52
Skin lesions caused by Mycobacterium haemophilum. Ann Intern Med (1982) 1.50
Effects of nonleukemogenic and wild-type Moloney murine leukemia virus on lymphoid cells in vivo: identification of a preleukemic shift in thymocyte subpopulations. J Virol (1986) 1.47
Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med (1990) 1.46
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. Control Clin Trials (2001) 1.39
Toxigenic Vibrio cholerae O1 strain from Mexico identical to United States isolates. Lancet (1983) 1.39
Fatal cutaneous necrosis mimicking calciphylaxis in a patient with type 1 primary hyperoxaluria. Arch Dermatol (1995) 1.39
Ureolytic Escherichia coli of human origin: serological, epidemiological, and genetic analysis. J Clin Microbiol (1979) 1.35
Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology (1991) 1.31
Hemolytic activity in enterotoxigenic and non-enterotoxigenic strains of Escherichia coli. J Clin Microbiol (1980) 1.25
"Enteropathogenic serotypes" of Escherichia coli which really are not. J Pediatr (1977) 1.22
Disease from infection with Vibrio mimicus, a newly recognized Vibrio species. Clinical characteristics and edipemiology. Ann Intern Med (1983) 1.21
Pulmonary blood volume in rheumatic heart disease and its alteration by isoproterenol. Circulation (1963) 1.17
Serological comparison of two collections of Vibrio cholerae non O1. J Clin Microbiol (1982) 1.14
Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer (1991) 1.14
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials (2001) 1.12
Disease from infection with Vibrio mimicus, a newly recognized Vibrio species. Ann Intern Med (1983) 1.11
Generation of infectious Moloney murine leukemia viruses with deletions in the U3 portion of the long terminal repeat. Mol Cell Biol (1986) 1.10
Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. J Am Geriatr Soc (1991) 1.10
Colonic complications of pancreatitis. Am Surg (1994) 1.09
Preleukemic hematopoietic hyperplasia induced by Moloney murine leukemia virus is an indirect consequence of viral infection. J Virol (1990) 1.08
Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J (2002) 1.08
Response of rat lung to inhaled tobacco smoke with or without prior exposure to 3,4-benzpyrene (BP) given by intratracheal instillation. Br J Cancer (1975) 1.08
The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation (1987) 1.06
Response of rat lung to inhaled vapour phase constituents (VP) of tobacco smoke alone or in conjunction with smoke condensate or fractions of smoke condensate given by intratracheal instillation. Br J Cancer (1975) 1.04
The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med (1992) 1.04
Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet (1975) 1.03
Yersinia enterocolitica pharyngitis. Ann Intern Med (1983) 1.03
Occupational physical activity and other risk factors for preterm birth among US Army primigravidas. Am J Public Health (1990) 1.02
Application of SFHR to gene therapy of monogenic disorders. Gene Ther (2002) 1.01
A non-O1 Vibrio cholerae isolated from a goose. Avian Dis (1981) 0.99
Experience with infusion and resection in cancer of the liver. Surg Gynecol Obstet (1974) 0.98
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol (1999) 0.96
Response of rat lung to tobacco smoke condensate or fractions derived from it administered repeatedly by intratracheal instillation. Br J Cancer (1975) 0.96
Parametric studies of tinnitus masking and residual inhibition. Br J Audiol (1983) 0.95
Serotypes of enterotoxigenic Escherichia coli isolated in the United States. Infect Immun (1980) 0.95
Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension (1991) 0.95
Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation (1996) 0.94
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo. J Virol (1985) 0.93
Patterns of glycosaminoglycan/proteoglycan immunostaining in human skin during aging. J Invest Dermatol (1991) 0.93
Liposomes modulate human immunodeficiency virus infectivity. J Gen Virol (1990) 0.93
Eleven years' experience with hyperthermic perfusion for melanoma of the extremities. World J Surg (1979) 0.92
In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line. Blood (1994) 0.91
Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Stat Med (1992) 0.91
Comparative observation of fibroblasts derived from the papillary and reticular dermis of infants and adults: growth kinetics, packing density at confluence and surface morphology. Mech Ageing Dev (1985) 0.90
Enhancement of human immunodeficiency virus type 1 infection by cationic liposomes: the role of CD4, serum and liposome-cell interactions. J Gen Virol (1991) 0.90
Results of eleven years' experience with heated perfusion for melanoma of the extremities. Cancer Res (1979) 0.89
Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother (2007) 0.88
Potassium conductance models related to an interactive subunit membrane. J Membr Biol (1974) 0.86
Biochemical and serological characteristics of Serratia marcescens isolated from various clinical and environmental sources. Arch Roum Pathol Exp Microbiol (1976) 0.86
Treatment of carcinoma of the breast. Surg Gynecol Obstet (1979) 0.85
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens (1995) 0.85
Biomechanical consequences of replacement of the anterior cruciate ligament with a patellar ligament allograft. Part I: insertion of the graft and anterior-posterior testing. J Bone Joint Surg Am (1996) 0.85
Isolation and molecular characterization of the human CD34 gene. Blood (1992) 0.85
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials (2001) 0.85
Addition of three new serotypes of Shigella boydii to the Shigella schema. J Clin Microbiol (1985) 0.85
Standardized physician preparation of death certificates. Control Clin Trials (1987) 0.84
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharmacogenomics J (2012) 0.84
Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J (1994) 0.83
Dynamic measurement of the viscoelastic properties of skin. J Biomech (1991) 0.83